Member Info for B2HS2L

J_t:

Whilst AVA3996 is not our No 1 priority, - if we attract a development partner, then it will become a priority.

So I've reserved a place for news along those lines.

From our new Chairman - "We are pleased to confirm the addition of Darlene Deptula-Hicks to the Avacta Board. Darlene brings both commercial acumen and deep CAPITAL MATKETS experience, both invaluable to growing biotechnology companies. We look forward to the benefit of her expertise and experience."

Viva la Evolution CC.

...."They won't be trying to build Avacta into Glaxosmithkline"

or perhaps even GlaxoAlastairsmithkline.

...Anything that gets the convertible bond outstanding amount reduced is a priority.

Dr Fiona McLaughlin - ...just saying.

From 19.06.2023 RNS:

Shaun has held a number of senior and executive commercial positions over more than 30 years in companies in pharmaceutical and pharmaceutical services industries. These include at Pfizer, Sanofi, Wolters Kluwer Health and KnowledgePoint360 Group (now part of UDG Healthcare).

Dr Eliot Forster, Chairman of the Board of Avacta Group plc commented:

"Along with my fellow Directors I am delighted to welcome Shaun to the Board of Avacta Group. He brings a wide range of highly relevant commercial experiences from successful healthcare businesses with similar ambitions for growth that we have in Avacta. I know Shaun will positively impact our shared thinking and I'm excited to have him join the company."

Dr Alastair Smith, Chief Executive of Avacta Group plc commented:

"I am delighted that Shaun has joined the Board of Avacta Group. He brings deep and extensive commercial experience to further strengthen the senior leadership of the Group as it executes its strategy across two divisions to build a major global healthcare business working to improve people's health and well-being through innovative oncology drugs and powerful diagnostics."

Shaun Chilton, Non-Executive Director of Avacta Group, commented:

"Avacta Group is building a high value, global business that is seeking to significantly improve people's health and well-being. I am excited to leverage my own broad experience of growing healthcare businesses and working with the other members of the Board to help guide Avacta to meet its very significant potential."

++++++++++

I'm surprised it's taken a year and a change of CEO for Avacta to avail of his services.

A deal maker is pulling the strings.... are you saying it's the same deal maker who's purpose was to place

SC becoming a NED.

The recent radio silence would appear to be based on a boardroom battle, and at last Shaun Chilton has found his voice.

I marvelled at how quiet he was, wondering why he was on the board when the latest raise went through.

Very good news, and well done CC, this signals more change imminently.

Viva la evolution!

Would a new NDA from negotiation with an interested party(s) now preclude the company

using RNS's to update shareholders concerning trial progress.

Rambo & j_t

"....they should have had two RNSs, IMO. The first with the SMDC thumbs up and the second when all three C2 patients were dosed."

Question for the AGM here:

Progress of trial is standard fare for good communications from company to shareholders.

If they can't get this right, then comms are more screwed than we thought.

TAKEAWAYS:

Para 1 complete. -

note: The terms of the *SCHEDULE* do not form part of the court order and so may remain confidential.

Application

More appropriate uses can be observed in commercial litigation, such as:

✅ when terms are agreed without admission of liability;

✅ where the parties have agreed that certain terms will remain confidential.

The Tomlin order will contain the orders that the parties would like the court to make, such as staying the proceedings, making relevant orders for costs and granting permission to apply. The other settlement terms will be contained in the *SCHEDULE* to the order.

ie Don't expect too see too much detail if we ever see this document.

That's my take.

From caseboard: 11.06.2024: Order by Judge - Tomlin Order

From Wikipedia, the free encyclopedia

A Tomlin order is a court order in the English civil justice system under which a court action is stayed on terms that have been agreed in advance between the parties and are included in a schedule to the order. As such, it is a form of consent order. The Tomlin order permits either party to apply to court to enforce the terms of the order, which avoids the need to start fresh proceedings. The terms of the schedule do not form part of the court order and so may remain confidential, and they may include matters outside the jurisdiction of the court or the scope of the case in hand.

Application

The order has seen significant use in the settlement of personal injury litigation, although there has been debate as to whether that is the best option. It is neither necessary nor appropriate where the settlement simply involves the payment of money. More appropriate uses can be observed in commercial litigation, such as:

when terms are agreed without admission of liability;

where the terms are complicated or go beyond what the court has jurisdiction to order; or

where the parties have agreed that certain terms will remain confidential.

The Tomlin order will contain the orders that the parties would like the court to make, such as staying the proceedings, making relevant orders for costs and granting permission to apply. The other settlement terms will be contained in the schedule to the order.

In any subsequent application to the court, there will be jurisdiction to vary only the order itself but not what appears in the schedule, which has been characterized by Lord Steyn as being in effect a commercial agreement. It can be attacked only if it is subsequently discovered that the settlement was obtained by way of fraud. Where fraud was initially alleged to have occurred earlier in the proceedings, but a settlement was subsequently reached and incorporated into an order, the matter cannot be reopened later on if "better evidence of the fraud came to light than was available when the settlement contract was made."

FWIW -

https://www.labpulse.com/business-insights/policy-and-regulation/fda-clearance/article/15677136/roche-garners-fda-eua-for-4in1-respiratory-panel?braze_int_id=64b7b1a59c412b0001d02d21&braze_ext_id=64b7b1a07ab161fb33c6ea4c

Roche garners FDA EUA for 4-in-1 respiratory panel

LabPulse.com staff writers

Jun 10, 2024

Roche has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Cobas Liat SARS-CoV-2, influenza A/B, and respiratory syncytial virus (RSV) nucleic acid test.

The rapid multiplex real-time reverse transcription polymerase chain reaction assay is designed for use on the Cobas Liat system. It can detect and differentiate between SARS-CoV-2, the influenza A and B viruses, and RSV from either a single nasopharyngeal or anterior nasal swab sample and produces results in **20 minutes**.

The test is authorized for use at point-of-care settings operating under a CLIA certificate of waiver, certificate of compliance, or certificate of accreditation.

In a statement, Roche noted that it intends to pursue FDA 510(k) clearance and a CLIA waiver for the test; the company has plans for commercial launch in other markets worldwide after gaining CE-IVDR approval.

The new assay expands Roche's portfolio of tests for respiratory illnesses for the Cobas Liat system, which already includes tests for SARS-CoV-2, strep A, SARS-CoV-2 and influenza A/B, and influenza A/B and RSV.

++++

Length of time for these clearances unknown.

Energyshares - re your original post:

"Could Avacta offer Lilly extra exclusive licenses to the pre|CISION technology for use in a few more radiopharmaceutical prodrugs.

Under the terms of the Point agreement, Avacta will receive an upfront fee and development milestones for the first radiopharmaceutical prodrug totalling $9.5 million. Avacta will also receive milestone payments for subsequent radiopharmaceutical prodrugs of up to $8 million each, a royalty on sales of FAP-activated radiopharmaceuticals by POINT and a percentage of any sublicensing income received by POINT."

If Avacta were to offer Lilly one extra exclusive licence for use in one more radiopharmaceutical prodrug, at an attractive price, might the announcement of that deal, show other interested parties that Lilly were making use and benefitting further from their purchase of Point Bio.

This could encourage others to the negotiating table and 'get this party started'

in terms of signing deals targeting therapies to tumours and avoiding systemic toxicities.

Just a thought.

An out of court settlement meeting has taken place in the last 36 hours.

Despite all the agreement between the sides, (30.04.2024 - https://www.bailii.org/ew/cases/EWHC/TCC/2024/1071.html) it was clear that each side had points to be made which could only be settled in court.

Andrew Twigger QC wanted his day in court, hired by James Wakefield (JW), Chairman Novacyt, possibly to use the case as an exhibition for the benefit of his many and varied business interests, to show he meant business by hiring a very successful QC to represent the company in dispute with DHSC.

The fact Twigger was keen to use the High Court to defend the claim, to me shows there was much about his plans that should have led to a successful defence.

And a successful defence was necessary to protect and ensure the reputation of Primerdesign and Novacyt, for quality assays that did what they said on the IFU, and the reputation was shown to be enhanced.

However, *IF* the DHSC threatened to appeal unless the claim was awarded in full by the court, then that would have left JW and Twigger in a dark place.

Same old story, - the government can afford to take this all the way, and the cost of mounting the defence has already been considerable, with many more millions guaranteed to be necessary to win justice.

And how long might this take to pan out? - Nobody knows, certainly years plural.

Financially Novacyt need to stop the drain of funds on Twigger & Co's services, and draw a line under the dispute.

I believe something like this transpired.

Perhaps when Twigger wanted to take the case to court, he wasn't being genuine, but for sure JW was, Novacyt had already paid for most of Twiggers services.

If Twigger was serious, then a KC of his standing would have known he could defend the claim successfully, and pursue the counterclaim.

But JW would know it would have been a pyric victory for Novacyt because the appeal process would have been a bridge too far for a small company, and funds have been assigned elsewhere within Yourgene.

I'm aware there is supposition in what I have stated, but this is an attempt to place todays announcement in context.

*IF* the above is in the right ball park, then I cannot understand why we ended up paying £5M to DHSC. They sued us, we had no choice but to defend ourselves.

Perhaps DHSC said pay our court costs or we take the commercial settlement of all claims and counterclaims off the table, and you take your chance in court, but we are certain to appeal.

£5M is a trifle to the DHSC, who operate with tax payers money all day every day, with much much larger sums, and don't give a damn about business reputations.

"Just a thought, after yesterdays result,

If we had not spent the cash on Ygen would the sp have fared different,thoughts anyone ?."

I believe the sp would reflect that Novacyt was being run for the benefit of the BoD's salaries,

a cash cow with no plans to Merge or Acquire anything.

Share buying possibly prior to AGM, would probably go down well with shareholders.

If Directors were to buy, that's when I think it would happen.

A remote AGM will not help the current shareholder / Bod disconnect though.

Please consider filtering.

Believe Wilson and I, it's so peaceful, safe in the knowledge that nothing of any use has been posted by PI here, ever.

Would you not take the £5M settlement out of that provision so £14.5 M is returned to cash?

Thanks for the confirmation

over and OUT.

Filtered

We have financial certainty - what's that worth after 3 years.

We also have the threat of court action removed, what's that worth to any predator interested?

We'll see.